Drug combination assays using Caenorhabditis elegans as a model system

被引:2
|
作者
Hernando, Guillermina [1 ]
Bouzat, Cecilia [1 ]
机构
[1] Univ Nacl Sur UNS, Dept Biol Bioquim & Farm, Inst Invest Bioquim Bahia Blanca, CONICET, RA-8000 Bahia Blanca, Argentina
关键词
Drug combination; Synergistic effect; Nematode; Anthelmintic drug; Drug resistance; Locomotion assays; Pharmacological treatments; Thymol; Levamisole; DISCOVERY;
D O I
10.1016/j.vascn.2025.107583
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The C. elegans drug combination assay evaluates the effects of drug combinations in the nematode Caenorhabditis elegans, serving as a valuable tool to assess the efficacy of pharmaceutical agents and natural compounds. Using C. elegans as a model organism, this method allows for the efficient screening of the combined effects of different drugs and evaluation of synergistic effects in drug combinations, which reduces the risk of developing drug resistance. Combination therapy, involving commercial drugs, new agents, or natural products, broadens treatment effectiveness by targeting multiple pathways, effectively managing complex diseases with minimized side effects. The method focuses on discovering effective drug combinations, such as anthelmintic drugs, streamlining earlystage drug discovery to save time and resources. Additionally, its versatility allows for application across most areas of pharmacology and toxicology, extending its usefulness beyond anthelmintic treatments. In the experiments, synchronized worms are exposed to different drug concentrations to evaluate behavioral changes, mostly alterations in worm locomotion. Concentration-response curves for changes in behavior are generated and EC50 or IC50 values determined for the individual drugs. To determine whether the effects of a drug combination are synergistic, additive, or antagonistic, at least three different concentration ratios must be tested. These combinations are then analyzed using specialized drug combination analysis software. This methodology ensures consistent and precise outcomes and evaluates drug impacts on worm behavior parameters crucial for effective pharmacological activity. In conclusion, the C. elegans drug combination assay provides critical insights for developing successful market formulations applicable across a wide range of pharmacological treatments. Its ability to efficiently screen for synergistic, additive, or antagonistic effects makes it a valuable tool for identifying effective therapeutic strategies, potentially reducing drug resistance and improving treatment outcomes in various medical and toxicological fields.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Caenorhabditis elegans for preclinical drug discovery
    Arya, Upasna
    Das, Chinmaya Kumar
    Subramaniam, Jamuna R.
    CURRENT SCIENCE, 2010, 99 (12): : 1669 - 1680
  • [32] Understanding the molecular basis of Alzheimer’s disease using a Caenorhabditis elegans model system
    Collin Y. Ewald
    Chris Li
    Brain Structure and Function, 2010, 214 : 263 - 283
  • [33] Understanding the molecular basis of Alzheimer's disease using a Caenorhabditis elegans model system
    Ewald, Collin Y.
    Li, Chris
    BRAIN STRUCTURE & FUNCTION, 2010, 214 (2-3): : 263 - 283
  • [34] Nematicidal effect of plumbagin on Caenorhabditis elegans: a model for testing a nematicidal drug
    Chaweeborisuit, Phantip
    Suriyonplengsaeng, Chinnawut
    Suphamungmee, Worawit
    Sobhon, Prasert
    Meemon, Krai
    ZEITSCHRIFT FUR NATURFORSCHUNG SECTION C-A JOURNAL OF BIOSCIENCES, 2016, 71 (5-6): : 121 - 131
  • [35] Caenorhabditis elegans-based Model Systems for Antifungal Drug Discovery
    Anastassopoulou, Cleo G.
    Fuchs, Beth Burgwyn
    Mylonakis, Eleftherios
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (13) : 1225 - 1233
  • [36] Caenorhabditis elegans as a Model to Study the Molecular and Genetic Mechanisms of Drug Addiction
    Engleman, Eric A.
    Katner, Simon N.
    Neal-Beliveau, Bethany S.
    MOLECULAR BASIS OF DRUG ADDICTION, 2016, 137 : 229 - 252
  • [37] Glutathione synthesis in parasitic nematodes:: Caenorhabditis elegans as a model system
    Ajonina, C
    Sommer, A
    Lüersen, K
    Liebau, E
    Walter, RD
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 293 : 109 - 110
  • [38] Caenorhabditis elegans as a Model System to Study Human Neurodegenerative Disorders
    Roussos, Antonis
    Kitopoulou, Katerina
    Borbolis, Fivos
    Palikaras, Konstantinos
    BIOMOLECULES, 2023, 13 (03)
  • [39] Quality improvement of mitochondrial respiratory chain complex enzyme assays using Caenorhabditis elegans
    Chen, Xiulian
    Thorburn, David R.
    Wong, Lee-Jun
    Vladutiu, Georgirene D.
    Haas, Richard H.
    Le, Thuy
    Hoppel, Charles
    Sedensky, Margaret
    Morgan, Philip
    Hahn, Si Houn
    GENETICS IN MEDICINE, 2011, 13 (09) : 794 - 799
  • [40] CAENORHABDITIS-ELEGANS - A MODEL SYSTEM FOR SPACE BIOLOGY STUDIES
    JOHNSON, TE
    NELSON, GA
    EXPERIMENTAL GERONTOLOGY, 1991, 26 (2-3) : 299 - 309